Biotech Job Trends: Week Ending April 20, 2026

Welcome to the first edition of Biotech Job Trends, a weekly snapshot of hiring activity across the biotech and biopharma companies tracked in Company Canary. Each week we'll surface what's changing in the job market — who's expanding, who's slowing down, which roles are in demand, and what that tells us about where the industry is headed.

A quick note on scope: the companies below reflect what Company Canary users have asked us to track, not a full biotech index. We add new companies every week, so coverage is broadening fast — but for now, treat this as a directional signal, not a representative survey of the entire industry. For this week's post, we've also excluded a handful of very large employers (Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca) along with two non-biotech trackers (Doximity, Zanskar) so the view isn't dominated by a few mega-cap posting volumes.

As of Monday, April 20, 2026:

That's the working canvas for the rest of this post.

Nine new companies entered the tracker over the past seven days, and every one of them brought at least 5 active job postings with it. The lineup is a good showcase of the breadth Company Canary now covers — from Alphabet-backed AI drug discovery labs to commercial-stage radiopharmaceutical players:

• Revolution Medicines — 236 active jobs. Clinical-stage oncology focused on RAS(ON) inhibitors. By far the biggest new addition this week.
• Telix Pharmaceuticals — 34 active jobs. Commercial-stage radiopharmaceuticals, ASX-listed.
• Eikon Therapeutics — 33 active jobs. Platform company built around super-resolution live-cell imaging for drug discovery.
• Isomorphic Labs — 29 active jobs. Alphabet's AI-first drug discovery spinout, headquartered in London.
• Cytokinetics — 25 active jobs. Muscle biology focus, approaching first approval in obstructive hypertrophic cardiomyopathy.
• Kailera Therapeutics — 23 active jobs. Obesity and metabolic disease, recently stood up with a Hengrui-licensed GLP-1 asset.
• Intellia Therapeutics — 22 active jobs. In vivo CRISPR gene editing.
• Formation Bio — 19 active jobs. AI-native "tech-bio" building its own clinical development engine.
• Iambic Therapeutics — 16 active jobs. AI-driven small-molecule discovery, San Diego.

Between them: oncology, gene editing, AI-first platforms, radiopharmaceuticals, cardiovascular, and metabolic. That's most of the modalities a modern biotech job seeker would plausibly care about, and a decent cross-section of company stages — from pre-commercial platforms to publicly traded companies approaching launch.

767 new job postings appeared across all tracked companies this past week. Of those, 315 were posted at companies that were already in the tracker before April 13 — so these are genuinely new roles at established employers, not artifacts of newly-added companies flooding in.

Three roles worth a look

A few postings stood out as interesting reads on where specific companies are investing:

1. Vertex Pharmaceuticals — Chief of Staff / Strategy and Operations Lead to SVP, Research (Boston, MA). A senior internal-operator role sitting next to research leadership. Companies tend to open these when they're about to make big bets on portfolio shape.
2. Tempus AI — Customer Success AI Strategy & Agent Development Lead (Chicago). A commercial-side role explicitly scoped around building AI agents into customer workflows. Tempus is wiring agentic AI directly into how customers use the product, not just the back-end.
3. Regeneron — Associate Scientist, Protein Biochemistry (siRNA Therapeutics, Lipid Nanoparticles) (Tarrytown, NY). Regeneron has historically been an antibody house. Staffing up in siRNA + LNP is one of the more legible signals of a modality expansion beyond their core.

Where the volume is coming from

A handful of existing companies did most of this week's hiring:

• Regeneron (72 new postings) — the broadest hirer of the week, with roles spanning R&D, QA, manufacturing, medical affairs, finance, and procurement. Tarrytown and Sleepy Hollow dominate the geography.
• Vertex Pharmaceuticals (33 new postings) — heavy on commercial and medical affairs for the US Pain franchise (they've been gearing up for suzetrigine), plus several senior R&D hires including the Chief of Staff role above.
• Biogen (32 new postings) — skewed toward market insights, analytics, and portfolio strategy, with several Alzheimer's-specific roles. Reads like a company doubling down on commercial execution.
• Moderna (26 new postings) — and this is the most interesting cluster of the week: 8 of those 26 roles are in Analytical Development or Analytical Technical Operations, ranging from Research Associate up through Director. A concentrated burst of CMC/analytical hiring usually signals a meaningful push on manufacturing scale-up or a new modality entering process development.
• Neurocrine Biosciences (26 new postings) — 5 new field sales reps in a single week (NeuroPsych Account Specialists in Nashville, Brooklyn, Poughkeepsie, plus a Long Term Care rep in Salt Lake City and a Rare Disease rep in Cincinnati). Field-force expansion on this cadence usually maps to a commercial ramp.
• Exact Sciences (26 new postings) — notably diverse mix, including IT/SAP, clinical, and on-site hospitality roles at their Madison HQ campus.

Seniority skew of this week's new roles

Across the 315 new postings at existing companies, the tilt is distinctly toward individual contributors:

Level	Share of new roles
Individual Contributor	27.9%
Senior (IC)	14.6%
Manager	12.1%
Principal / Staff / Lead	10.2%
Senior Manager	7.9%
Director	7.6%
Associate Director	5.7%
Intern / Trainee	3.2%
Senior Director	2.5%
Executive Director	0.3%
VP+	1.3%

Roughly 53% of this week's new roles are IC through Senior IC / Principal level — companies are filling out execution capacity, not expanding leadership benches.

Zooming out from the week to the full set of 2,743 active postings, here's what the landscape looks like right now.

Seniority

Compared to the weekly inflow, the current active pool is more senior-weighted:

• ~30% director-and-above (Associate Director through VP+)
• ~20% manager-level (Manager + Senior Manager)
• ~9% principal / staff / lead
• ~30% IC / senior IC / other individual contributors
• ~2% intern or trainee roles

Biotech-biopharma has always been matrix-heavy, with unusually deep director benches relative to tech — this confirms that shape.

Geography

Boston leads, unsurprisingly, and Remote comes in third:

Region	Share of active jobs
Boston / Cambridge MA	15.0%
NY / NJ metro	12.6%
Remote	11.4%
SF Bay Area	9.6%
San Diego CA	7.4%
Europe / UK	4.7%
Asia-Pacific	4.1%
Madison WI	2.0%
Research Triangle NC	1.9%
Chicago IL	1.5%

The NY/NJ number is inflated by Regeneron's Tarrytown and Sleepy Hollow campuses — take that with context. Roughly 15% of all postings are either explicitly Remote or US Remote, which is higher than most tech-adjacent industries these days.

Function

A rough functional bucketing of active postings (these are approximate — title parsing only goes so far):

Function	Share
Commercial & Marketing	15.3%
Clinical & Medical	15.1%
Manufacturing & Operations	11.3%
Research & Discovery	11.2%
Regulatory & Quality	7.8%
Data, IT & Digital	6.8%
Finance & Legal	3.5%
Engineering (other)	2.4%
Other / uncategorized	~26%

Commercial and Clinical are near-tied at the top, and together with Manufacturing and Research they account for more than half of all active postings. Data/IT/Digital at ~7% is worth watching — a year from now, we'll see whether that share is climbing as more companies commit to AI-first operating models.

• All figures reflect the state of the Company Canary database as of Monday, April 20, 2026.
• The dataset excludes seven companies for this post: Sanofi, Pfizer, Eli Lilly, Amgen, AstraZeneca (whose posting volumes would dominate the numbers), and two non-biotech entries (Doximity, Zanskar).
• Coverage is driven by what Company Canary users choose to track. It is not a representative sample of the biotech industry as a whole, and it tilts toward publicly-traded companies and well-known private ones. New companies are added every week, so the denominator will keep growing.
• Seniority and function classifications are derived from job titles using pattern matching, so they're directional rather than exact. Geography is normalized from raw location strings and rolled up into metros or regions.

See you next Monday.